Progressive multifocal leukoencephalopathy associated with elranatamab therapy in relapsed/refractory multiple myeloma
Journal of Oncology Pharmacy Practice
Published online on January 28, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionElranatamab, a bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, has demonstrated remarkable efficacy in relapsed or refractory multiple myeloma (RRMM). With the growing clinical use of BCMA-directed bispecific antibodies,...
IntroductionElranatamab, a bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, has demonstrated remarkable efficacy in relapsed or refractory multiple myeloma (RRMM). With the growing clinical use of BCMA-directed bispecific antibodies,...